Raymond James Financial Inc. Makes New $584,000 Investment in BioNTech SE (NASDAQ:BNTX)

Raymond James Financial Inc. purchased a new stake in shares of BioNTech SE (NASDAQ:BNTX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 5,122 shares of the company’s stock, valued at approximately $584,000.

Several other institutional investors and hedge funds have also modified their holdings of BNTX. abrdn plc increased its position in BioNTech by 70.7% during the fourth quarter. abrdn plc now owns 385,668 shares of the company’s stock worth $43,947,000 after buying an additional 159,676 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of BioNTech by 123.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 134,036 shares of the company’s stock valued at $15,919,000 after acquiring an additional 74,119 shares during the last quarter. Flossbach Von Storch SE raised its stake in shares of BioNTech by 1.1% in the 4th quarter. Flossbach Von Storch SE now owns 4,406,843 shares of the company’s stock valued at $502,160,000 after acquiring an additional 47,236 shares in the last quarter. Exome Asset Management LLC acquired a new stake in BioNTech in the 3rd quarter worth approximately $4,104,000. Finally, SG Americas Securities LLC lifted its holdings in BioNTech by 412.3% in the 4th quarter. SG Americas Securities LLC now owns 41,470 shares of the company’s stock worth $4,726,000 after purchasing an additional 33,375 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Stock Down 4.3 %

BNTX opened at $88.05 on Monday. The company has a market capitalization of $21.13 billion, a P/E ratio of -41.93 and a beta of 1.07. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The firm’s fifty day moving average price is $108.81 and its two-hundred day moving average price is $112.78. BioNTech SE has a fifty-two week low of $76.53 and a fifty-two week high of $131.49.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.70. The business had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm’s revenue was down 19.5% on a year-over-year basis. During the same period in the previous year, the business earned $1.90 EPS. On average, analysts anticipate that BioNTech SE will post -3.88 EPS for the current year.

Analyst Upgrades and Downgrades

BNTX has been the topic of a number of recent analyst reports. Truist Financial assumed coverage on shares of BioNTech in a research report on Friday, January 10th. They issued a “buy” rating and a $172.00 price target on the stock. BMO Capital Markets raised their target price on shares of BioNTech from $130.00 to $143.00 and gave the company an “outperform” rating in a research note on Tuesday, March 11th. HC Wainwright cut their target price on shares of BioNTech from $150.00 to $145.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $171.44 price target on shares of BioNTech in a research report on Tuesday, March 11th. Finally, Morgan Stanley cut their price objective on BioNTech from $145.00 to $139.00 and set an “overweight” rating for the company in a research report on Tuesday, March 11th. Three research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, BioNTech currently has an average rating of “Moderate Buy” and an average price target of $143.44.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.